Alminoprofen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Alminoprofen
Accession Number
DB13314
Type
Small Molecule
Groups
Experimental
Description

Alminoprofen is a non-steroidal anti-inflammatory drug.

Structure
Thumb
Synonyms
  • 2-{4-[(2-methylprop-2-en-1-yl)amino]phenyl}propionic acid
  • alminoprofene
  • alminoprofeno
  • alminoprofenum
  • p-((2-Methylallyl)amino)hydratropic acid
  • α-methyl-4-[(2-methyl-2-propenyl)amino]benzeneacetic acid
External IDs
EB 382 / EB-382
International/Other Brands
Minalfen
Categories
UNII
0255AHR9GJ
CAS number
39718-89-3
Weight
Average: 219.284
Monoisotopic: 219.125928791
Chemical Formula
C13H17NO2
InChI Key
FPHLBGOJWPEVME-UHFFFAOYSA-N
InChI
InChI=1S/C13H17NO2/c1-9(2)8-14-12-6-4-11(5-7-12)10(3)13(15)16/h4-7,10,14H,1,8H2,2-3H3,(H,15,16)
IUPAC Name
2-{4-[(2-methylprop-2-en-1-yl)amino]phenyl}propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(NCC(C)=C)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Alminoprofen.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabAlminoprofen may increase the anticoagulant activities of Abciximab.Approved
AcebutololAlminoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAlminoprofen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Alminoprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Alminoprofen.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Alendronic acid.Approved
AliskirenAlminoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololAlminoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Alminoprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Alminoprofen is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideAlminoprofen may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Alminoprofen.Approved
AncrodAlminoprofen may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Alminoprofen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Alminoprofen.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Antipyrine.Approved, Investigational
Antithrombin III humanAlminoprofen may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Antrafenine.Approved
ApixabanAlminoprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Alminoprofen.Investigational
ApramycinAlminoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Alminoprofen.Approved, Investigational
ArbekacinAlminoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinAlminoprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanAlminoprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololAlminoprofen may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineAlminoprofen may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Atamestane.Investigational
AtenololAlminoprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alminoprofen.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Alminoprofen.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Alminoprofen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Alminoprofen.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Alminoprofen is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Balsalazide.Approved, Investigational
BecaplerminAlminoprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Alminoprofen.Approved, Investigational
BefunololAlminoprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAlminoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Alminoprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Alminoprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Alminoprofen.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Alminoprofen.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Alminoprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololAlminoprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Alminoprofen.Approved, Investigational
BevantololAlminoprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Alminoprofen.Approved, Investigational
BisoprololAlminoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinAlminoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololAlminoprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Alminoprofen.Investigational
BucindololAlminoprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Alminoprofen.Approved
BufexamacThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Bufexamac.Approved, Experimental
BufuralolAlminoprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Alminoprofen.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Alminoprofen.Approved
BupranololAlminoprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Alminoprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Alminoprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Alminoprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololAlminoprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolAlminoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Alminoprofen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Celecoxib.Approved, Investigational
CeliprololAlminoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinAlminoprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Alminoprofen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Alminoprofen.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Alminoprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cimicoxib.Investigational
CinoxacinAlminoprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinAlminoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Alminoprofen.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Alminoprofen.Vet Approved
CloranololAlminoprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Alminoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Alminoprofen.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Alminoprofen.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Alminoprofen is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateAlminoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAlminoprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAlminoprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanAlminoprofen may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Delapril.Investigational
DesipramineAlminoprofen may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinAlminoprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Alminoprofen.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Alminoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Alminoprofen.Experimental
DextranAlminoprofen may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinAlminoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Alminoprofen.Approved, Vet Approved
DicoumarolAlminoprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Alminoprofen.Approved
DihydrostreptomycinAlminoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Alminoprofen.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Alminoprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Alminoprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Alminoprofen.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Alminoprofen.Approved
DrospirenoneAlminoprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Alminoprofen.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Alminoprofen.Investigational
Edetic AcidAlminoprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAlminoprofen may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Enalaprilat.Approved
EnoxacinAlminoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinAlminoprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Alminoprofen.Experimental
EpanololAlminoprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Alminoprofen.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Alminoprofen.Experimental
EplerenoneAlminoprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Alminoprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Alminoprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Equilin.Approved
EsatenololAlminoprofen may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololAlminoprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Alminoprofen.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateAlminoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Alminoprofen.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Alminoprofen.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Alminoprofen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Alminoprofen.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Alminoprofen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Alminoprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Alminoprofen.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Feprazone.Experimental
Ferulic acidAlminoprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Alminoprofen.Approved, Investigational
FleroxacinAlminoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Alminoprofen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fludrocortisone.Approved, Investigational
FluindioneAlminoprofen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineAlminoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Alminoprofen.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Alminoprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Alminoprofen.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Alminoprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxAlminoprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Alminoprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Fosinopril.Approved
FramycetinAlminoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Alminoprofen.Approved, Vet Approved
GabexateAlminoprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinAlminoprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAlminoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Alminoprofen.Approved, Withdrawn
GemifloxacinAlminoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAlminoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAlminoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAlminoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Alminoprofen.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Alminoprofen.Approved
GrepafloxacinAlminoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Guacetisal.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Alminoprofen.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Alminoprofen is combined with HE3286.Investigational
HeparinAlminoprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Alminoprofen.Investigational
HydralazineAlminoprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Alminoprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Alminoprofen.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Alminoprofen.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Alminoprofen.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Alminoprofen.Approved, Investigational
Hygromycin BAlminoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Alminoprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Alminoprofen.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Alminoprofen.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Icosapent.Approved, Nutraceutical
IdraparinuxAlminoprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Alminoprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Alminoprofen.Approved
IndenololAlminoprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Alminoprofen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Alminoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Alminoprofen.Approved, Investigational
IsepamicinAlminoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alminoprofen.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Istaroxime.Investigational
KanamycinAlminoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Alminoprofen.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Alminoprofen.Approved
LabetalolAlminoprofen may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
LandiololAlminoprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Alminoprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Alminoprofen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Alminoprofen.Approved, Investigational
LepirudinAlminoprofen may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
LetaxabanAlminoprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololAlminoprofen may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololAlminoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAlminoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Alminoprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Alminoprofen.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Alminoprofen.Experimental
LomefloxacinAlminoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Alminoprofen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alminoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Alminoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Alminoprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Alminoprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Alminoprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Mefenamic acid.Approved
MelagatranAlminoprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Meloxicam.Approved, Vet Approved
MepindololAlminoprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Alminoprofen.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Alminoprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Alminoprofen.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Alminoprofen.Approved, Vet Approved
MetipranololAlminoprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Alminoprofen.Approved
MetoprololAlminoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Alminoprofen.Investigational, Withdrawn
MicronomicinAlminoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Alminoprofen.Approved, Experimental
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Alminoprofen.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Alminoprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alminoprofen.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Alminoprofen.Approved
MoxifloxacinAlminoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alminoprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alminoprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Nabumetone.Approved
NadololAlminoprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinAlminoprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatAlminoprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Alminoprofen.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Alminoprofen.Investigational
Nalidixic AcidAlminoprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Alminoprofen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Alminoprofen is combined with NCX 1022.Investigational
NeamineAlminoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololAlminoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinAlminoprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Alminoprofen is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Nepafenac.Approved, Investigational
NetilmicinAlminoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Alminoprofen.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alminoprofen.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Alminoprofen.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Alminoprofen.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alminoprofen.Investigational
NorfloxacinAlminoprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinAlminoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Alminoprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alminoprofen.Approved
OlsalazineAlminoprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Alminoprofen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Alminoprofen.Vet Approved
OtamixabanAlminoprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Oxaprozin.Approved
Oxolinic acidAlminoprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololAlminoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alminoprofen.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Alminoprofen is combined with Paromomycin.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Alminoprofen.Approved, Investigational
PazufloxacinAlminoprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAlminoprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololAlminoprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateAlminoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateAlminoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Perindopril.Approved
PhenindioneAlminoprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonAlminoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alminoprofen.Approved, Investigational
PindololAlminoprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidAlminoprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Alminoprofen.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alminoprofen.Approved, Investigational
Piromidic acidAlminoprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorAlminoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinAlminoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Alminoprofen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pomalidomide.Approved
Potassium CitrateAlminoprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololAlminoprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Alminoprofen.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Alminoprofen.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Alminoprofen can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Alminoprofen.Approved, Investigational
PropafenoneAlminoprofen may decrease the antihypertensive activities of Propafenone.Approved
PropranololAlminoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Alminoprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Alminoprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Alminoprofen.Vet Approved
Protein CAlminoprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanAlminoprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAlminoprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinAlminoprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Alminoprofen.Investigational
PuromycinAlminoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Alminoprofen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinAlminoprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinAlminoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Risedronate.Approved, Investigational
RivaroxabanAlminoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinAlminoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinAlminoprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Alminoprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alminoprofen.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Alminoprofen.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Alminoprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Alminoprofen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Alminoprofen.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Alminoprofen.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Alminoprofen.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Alminoprofen.Investigational
SisomicinAlminoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAlminoprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Alminoprofen.Approved
SotalolAlminoprofen may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinAlminoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Alminoprofen.Investigational
StreptomycinAlminoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alminoprofen.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Alminoprofen.Approved, Investigational
SulodexideAlminoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Alminoprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Alminoprofen.Experimental
TacrolimusAlminoprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Alminoprofen.Approved
TalinololAlminoprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Alminoprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Alminoprofen.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Alminoprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Alminoprofen.Approved, Investigational
TemafloxacinAlminoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Alminoprofen.Vet Approved
TerbutalineAlminoprofen may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Alminoprofen.Approved
TertatololAlminoprofen may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Alminoprofen.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololAlminoprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Alminoprofen.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tixocortol.Approved, Withdrawn
TobramycinAlminoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Alminoprofen.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Alminoprofen.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Alminoprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Alminoprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneAlminoprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Alminoprofen.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Alminoprofen.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Alminoprofen.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Trolamine salicylate.Approved
TrovafloxacinAlminoprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinAlminoprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Alminoprofen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Alminoprofen.Approved, Investigational
VancomycinAlminoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
WarfarinAlminoprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAlminoprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Alminoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Alminoprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alminoprofen.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D01513
ChemSpider
2013
ChEBI
31190
ChEMBL
CHEMBL1765293
Wikipedia
Alminoprofen
ATC Codes
M01AE16 — Alminoprofen

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.676 mg/mLALOGPS
logP0.47ALOGPS
logP1.86ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)4.15ChemAxon
pKa (Strongest Basic)4.77ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity65.58 m3·mol-1ChemAxon
Polarizability24.78 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
Phenylalkylamines / Aniline and substituted anilines / Secondary alkylarylamines / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
2-phenylpropanoic-acid / Phenylalkylamine / Aniline or substituted anilines / Secondary aliphatic/aromatic amine / Monocyclic benzene moiety / Benzenoid / Amino acid or derivatives / Amino acid / Carboxylic acid derivative / Carboxylic acid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
substituted aniline, monocarboxylic acid, secondary amino compound, amino acid (CHEBI:31190)

Drug created on June 23, 2017 14:39 / Updated on August 02, 2018 06:50